ClinicalTrials.gg
RecruitingNCT06859333Updated Jul 8, 2025

Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers

A Phase 1 interventional study of Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg and Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg in Influenza and Viral Respiratory Infection, sponsored by Valenta Pharm JSC. Recruiting at 1 site in Russia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Valenta Pharm JSC · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.

Planned enrollment
13th of 15
36 · median 240
Started
2025
with 2 others
Phase 1
2 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 13th largest by planned enrollment, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 13th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Valenta Pharm JSC, or all of them as a file.
02

Study summary

This is a Single Center, First-in-human Study of Safety, Tolerability, and Pharmacokinetic Profile of Ascending Single and Multiple Doses of Ingavirin Forte, Capsules in Healthy Volunteers.

03

Conditions studied

  • Influenza
  • Viral Respiratory Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form by the healthy subject prior to any study activities.
  2. Males and females aged 18 to 45 years (inclusive) of Caucasian race.
  3. Verified "healthy" diagnosis (no abnormalities detected based on clinical, laboratory, and instrumental examination methods specified in the protocol).
  4. Blood pressure (BP) levels: systolic blood pressure (SBP) from 100 to 130 mm Hg (inclusive), diastolic blood pressure (DBP) from 70 to 85 mm Hg (inclusive).
  5. Heart rate (HR) from 60 to 89 beats per minute (inclusive).
  6. Respiratory rate (RR) from 12 to 20 breaths per minute (inclusive).
  7. Body temperature from 36.0°C to 36.9°C (inclusive).
  8. (BMI): 18.5 kg/m² ≤ BMI ≤ 30 kg/m², with a minimum body weight of ≥ 55 kg for men and ≥ 45 kg for women.
  9. Agreement to use adequate methods throughout the study and for 30 days after its completion; for women of - a negative urine pregnancy test result.

Non-inclusion criteria:

  1. Known allergic history.
  2. to imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopent-2,4-dien-4-yl)ethyl] diamide of malonic acid (XC9) and/or included in the study drug in the medical history.
  3. Drug intolerance to imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopent-2,4-dien-4-yl)ethyl] diamide of malonic acid (XC9) and/or excipients included in the study drug.
  4. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
  5. Evidence or history of chronic diseases of the kidneys, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, urogenital, and immune systems, as well as skin, hematopoietic and vision organs.
  6. History of GIT surgery (except for appendectomy at least 1 year prior to screening).
  7. Diseases/conditions that, in the judgment of the investigator, may affect the absorption, distribution, metabolism, or excretion of the study drug (SD).
  8. Acute infectious diseases less than 4 weeks before screening.
  9. Use of drugs that significantly affect hemodynamics, drugs affecting liver function (barbiturates, omeprazole, cimetidine, etc.), drugs that prolong the (antipsychotics (haloperidol, quetiapine, olanzapine, risperidone, sulpiride), antidepressants (fluoxetine, sertraline), antiarrhythmics (amiodarone), antibiotics (clarithromycin, azithromycin, moxifloxacin, levofloxacin, ciprofloxacin), antifungals (fluconazole), diuretics (furosemide)), less than 2 months before screening.
  10. Regular use of drugs less than 2 weeks before screening and single use of drugs less than 7 days before screening (including over-the-counter drugs, vitamins, dietary supplements, herbal medicines).
  11. Blood or plasma donation within 3 months before screening.
  12. Use of hormonal contraceptives (in women) within 2 months before the start of screening.
  13. Use of depot injections of any drugs less than 3 months before the start of screening.
  14. Pregnancy or lactation; positive urine pregnancy test for women of childbearing potential.
  15. Women of childbearing potential who have had unprotected sexual intercourse within 30 days prior to taking study medications with an unsterilized partner.
  16. Participation in another clinical trial less than 3 months prior to screening or concurrently with this study.
  17. Consumption of more than 10 units of alcohol per week in the last month before inclusion in the study or a history of alcoholism, drug addiction, or substance abuse.
  18. Smoking more than 10 cigarettes per day currently or having smoked that amount in the past 6 months prior to screening; unwillingness to refrain from smoking during their stay at the research center.
  19. Consumption of alcohol, caffeine, and xanthine-containing products within 7 days prior to taking the study drug.
  20. Consumption of citrus fruits, cranberries, rose hips and products containing them, preparations or products containing St. John's wort within 7 days prior to taking the study drug.
  21. Dehydration due to diarrhea, vomiting or other causes within the last 24 hours before taking the study drug.
  22. Positive blood test to (HIV) types 1 and 2; antibodies to Treponema pallidum antigens; surface antigen of virus (HBsAg); antibodies to virus antigens at screening.
  23. deviations on (ECG) in medical history and/or at screening including: QTcF interval (corrected by Fredericia) ≥430 ms in men and ≥450 ms in women.
  24. Information on risk factors for developing torsades de pointes such as heart failure, hypokalemia, family history of prolonged QT syndrome.
  25. Positive urine test for narcotic substances and potent medications at screening.
  26. Positive test for alcohol vapors at screening.
  27. Planning hospitalization during the study period for any reason other than hospitalization provided for by this protocol.
  28. Inability or unwillingness to comply with protocol requirements, perform procedures prescribed by the protocol, adhere to dietary and activity regimens.
  29. Belonging to a vulnerable group of volunteers: students from higher and secondary medical, pharmaceutical and dental educational institutions; junior staff from clinics and laboratories; employees of pharmaceutical companies; military personnel and prisoners; individuals in nursing homes; low-income and unemployed individuals; representatives of national minorities; homeless individuals; refugees; individuals under guardianship or custody; individuals unable to give consent; as well as law enforcement officers.
  30. Other conditions that, in the judgment of the investigator, may interfere with participation in the study or may lead to early withdrawal of the volunteer including adherence to fasting or special diets (e.g., vegetarianism, veganism, salt restriction) or a special lifestyle (night work hours, extreme physical exertion).

Exclusion criteria

Exclusion Criteria:

  1. The volunteer's withdrawal from further participation in the study.
  2. Non-compliance by the volunteer with the study participation rules (missed study procedures, self-administration of prohibited medications, violation of dietary and lifestyle restrictions, etc.).
  3. The emergence of reasons/situations during the study that threaten the safety of the volunteer (e.g., reactions, etc.).
  4. Volunteers selected for participation in the study who do not meet inclusion/exclusion criteria.
  5. Development of a severe adverse event (SAE) and/or serious adverse reaction (SAR) in the volunteer during the study.
  6. The volunteer requires or undergoes treatment that may affect the pharmacokinetics of the study drug.
  7. Missing two or more consecutive blood samples or three or more blood samples during one study period.
  8. The occurrence of vomiting/diarrhea within 8 hours after taking the study drug.
  9. Positive urine test for narcotic substances and potent medications.
  10. Positive test for alcohol vapors.
  11. Positive pregnancy test in female participants.
  12. The emergence of other reasons during the study that prevent the conduct of the study according to the protocol.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Single and multiple doses, 90 mg + 5 mg

    Ingavirin Forte, 1 capsule (90 mg + 5 mg) taken once under fasted conditions, followed by Ingavirin Forte, 1 capsule (90 mg + 5 mg) taken twice a day for 2 days (the first dose under fasted conditions, the second dose under fed conditions - 2 hours after a meal), and once in the morning under fasted conditions on the 3rd day. Wash-out period after a single-dose period will last from 7 to 21 days.

    Drug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg

  • Experimental
    Single and multiple doses, 90 mg + 10 mg

    Ingavirin Forte, 1 capsule (90 mg + 10 mg) taken once under fasted conditions, followed by Ingavirin Forte, 1 capsule (90 mg + 10 mg) taken twice a day for 2 days (the first dose on an under fasted conditions, the second dose under fed conditions - 2 hours after a meal), and once in the morning under fasted conditions on the 3rd day. Wash-out period after a single-dose period will last from 7 to 21 days.

    Drug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg

  • Experimental
    Single and multiple doses, 90 mg + 20 mg

    Ingavirin Forte, 1 capsule (90 mg + 20 mg) taken once under fasted conditions, followed by Ingavirin Forte, 1 capsule (90 mg + 20 mg) taken twice a day for 2 days (the first dose under fasted conditions, the second dose under fed conditions - 2 hours after a meal), and once in the morning under fasted conditions on the 3rd day. Wash-out period after a single-dose period will last from 7 to 21 days.

    Drug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg

Interventions

  • DrugCombined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg

    Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 5 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid

  • DrugCombined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg

    Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 10 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid

  • DrugCombined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg

    Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 20 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - Cmax

    Maximum plasma concentration (Cmax) of imidazolylethylamide of pentanedioic acid and N,N'-bis-\[2-(1,3-diazocyclopent-2,4-dien-4-yl)ethyl\] diamide of malonic acid. The same analytes would be used for other pharmacokinetic measures listed below.

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  2. Pharmacokinetics - tmax

    Time to reach Cmax (tmax)

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  3. Pharmacokinetics - AUC0-t

    Area under the plasma concentration-time curve from time 0 to t (AUC0-t)

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  4. Pharmacokinetics - AUC0-inf

    Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: From 0 hours extrapolated to infinity after single dose and from 48 hours extrapolated to infinity after multiple dose

  5. Pharmacokinetics - AUCextr

    Extrapolated AUC defined as (AUC0-inf - AUC0-t)/AUC0-inf

    Time frame: From 0 hours extrapolated to infinity after single dose and from 48 hours extrapolated to infinity after multiple dose

  6. Pharmacokinetics - t1/2

    Elimination half-life (t1/2)

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  7. Pharmacokinetics - kel

    Elimination constant (kel)

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  8. Pharmacokinetics - MRT

    Mean residence time (MRT)

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  9. Pharmacokinetics - Vd

    Volume of distribution

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  10. Pharmacokinetics - CL

    Clearance (CL)

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  11. Pharmacokinetics - number of terminal timepoints

    Number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant

    Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)

  12. Pharmacokinetics - AUC0-tau

    Steady state area under the plasma concentration-time curve from time 0 to t (AUC0-tau)

    Time frame: From 0 to 48 hours (multiple dose)

  13. Pharmacokinetics - Cmax,ss

    Steady state maximum plasma concentration (Cmax,ss)

    Time frame: From 0 to 48 hours (multiple dose)

  14. Pharmacokinetics - tmax,ss

    Steady state time to reach Cmax,ss (tmax,ss)

    Time frame: From 0 to 48 hours (multiple dose)

  15. Pharmacokinetics, urine - Aeinterval

    The amount of active substance excreted in urine during each time interval (Aeinterval), calculated as the concentration in urine multiplied by the volume of urine.

    Time frame: From 48 to 72 hours (multiple dose)

  16. Pharmacokinetics, urine - Ae(0-t)

    Total urinary excretion from zero to time t (Ae(0-t)), calculated as the sum of the amounts excreted during each time interval

    Time frame: From 48 to 72 hours (multiple dose)

  17. Pharmacokinetics, urine - Rmax

    Maximum rate of urinary excretion (Rmax), calculated by dividing the amount of active substance excreted during each time interval by the time over which it was collected

    Time frame: From 48 to 72 hours (multiple dose)

  18. Pharmacokinetics, urine - TRmax

    Time of maximum urinary excretion (TRmax), calculated as the average time interval during which Rmax was observed

    Time frame: From 48 to 72 hours (multiple dose)

  19. Pharmacokinetics, urine - Fe0-t

    Fraction (% of dose) excreted from the body unchanged (Fe0-t), calculated as Ae/orally administered dose

    Time frame: From 48 to 72 hours (multiple dose)

  20. Pharmacokinetics, urine - CLR

    Renal clearance (CLR), calculated as the ratio of Ae(0-t) to AUC(0-t)

    Time frame: From 48 to 72 hours (multiple dose)

Secondary outcomes

  1. Adverse event type

    Adverse events will be assessed by complaints, results of physical examination, results of heart rate and blood pressure assessment, results of respiratory rate assessment, body temperature, laboratory monitoring (clinical blood count, biochemical blood count, urinalysis), electrocardiography; adverse events will be classified in accordance to MedDRA.

    Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)

  2. Adverse event number

    Number of adverse events registered during the study

    Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)

  3. Adverse event severety

    Severity of adverse events registered during the study

    Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)

  4. Drop-outs associated with adverse events

    The number of cases of early termination of participation in the study due to the development of adverse events and/or serious adverse events associated with the study drug

    Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)

  5. Safety and Tolerability: volunteer complaints

    Description of any health-related complaints received from volunteer

    Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)

  6. Safety and Tolerability: physical examination results - cardiovascular system

    An assessment of the condition of the cardiovascular system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/cardiovascular symptoms, if any)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  7. Safety and Tolerability: physical examination results - respiratory system

    An assessment of the condition of the respiratory system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/respiratory symptoms, if any)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  8. Safety and Tolerability: physical examination results - digestive tract

    An assessment of the condition of the digestive tract and associated symptoms on physical examination (normal condition or a description of abnormal conditions/digestive tract symptoms, if any)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  9. Safety and Tolerability: physical examination results - endocrine system

    An assessment of the condition of the endocrine system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/endocrine symptoms, if any)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  10. Safety and Tolerability: physical examination results - musculoskeletal system

    An assessment of the condition of the musculoskeletal system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/musculoskeletal symptoms, if any)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  11. Safety and Tolerability: physical examination results - nervous system

    An assessment of the condition of the nervous system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/neurological symptoms, if any)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  12. Safety and Tolerability: physical examination results - sensory systems

    An assessment of the condition of the sensory systems and associated symptoms on physical examination (normal condition or a description of abnormal conditions/symptoms, if any

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  13. Safety and Tolerability: physical examination results - skin/visible mucous membranes

    An assessment of the condition of the skin/visible mucous membranes and associated symptoms on physical examination (normal condition or a description of abnormal conditions/symptoms, if any)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  14. Safety and Tolerability: vital signs - systolic blood pressure

    Systolic blood pressure (SBP, mmHg)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  15. Safety and Tolerability: vital signs - diastolic blood pressure

    Diastolic blood pressure (DBP, mmHg)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  16. Safety and Tolerability: vital signs - heart rate

    Heart rate (HR, bpm)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  17. Safety and Tolerability: vital signs - body temperature (Celsius temperature scale)

    Body temperature (Celsius temperature scale)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  18. Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: heart rate (beats per minute)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  19. Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  20. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  21. Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: corrected QT interval (distance from the beginning of the QRS complex to the end of the T wave; Fredericia correction)

    Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  22. Safety and Tolerability: clinical blood test - hemoglobin

    Hemoglobin (g/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  23. Safety and Tolerability: clinical blood test - hematocrit

    Hematocrit (%)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  24. Safety and Tolerability: clinical blood test - red blood cell count

    Red blood cell count (cells/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  25. Safety and Tolerability: clinical blood test - platelet count

    Platelet count (cells/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  26. Safety and Tolerability: clinical blood test - leukocyte count

    Leukocyte count (cells/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  27. Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate

    Erythrocyte sedimentation rate (mm/h)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  28. Safety and Tolerability: clinical blood test - myelocytes

    Leukocyte formula (myelocytes, %)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  29. Safety and Tolerability: clinical blood test - band neutrophils

    Leukocyte formula (band neutrophils, %)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  30. Safety and Tolerability: clinical blood test - segmented neutrophils

    Leukocyte formula (segmented neutrophils, %)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  31. Safety and Tolerability: clinical blood test - eosinophils

    Leukocyte formula (eosinophils, %)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  32. Safety and Tolerability: clinical blood test - basophils

    Leukocyte formula (basophils, %)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  33. Safety and Tolerability: clinical blood test - monocytes

    Leukocyte formula (monocytes, %)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  34. Safety and Tolerability: clinical blood test - lymphocytes

    Leukocyte formula (lymphocytes, %)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)

  35. Safety and Tolerability: urinalysis - specific gravity

    Specific gravity of the urine

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  36. Safety and Tolerability: urinalysis - color

    Color of the urine

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  37. Safety and Tolerability: urinalysis - transparency

    Transparency of the urine

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  38. Safety and Tolerability: urinalysis - pH

    pH of the urine

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  39. Safety and Tolerability: urinalysis - protein

    Protein concentration (g/L)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  40. Safety and Tolerability: urinalysis - glucose

    Glucose concentration (mmol/L)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  41. Safety and Tolerability: urinalysis - red blood cells

    Red blood cell content (number in sight)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  42. Safety and Tolerability: urinalysis - white blood cells

    White blood cell content (number in sight)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  43. Safety and Tolerability: urinalysis - epithelial cells

    Epithelial cell content (number in sight)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  44. Safety and Tolerability: urinalysis - casts

    Presence of casts (Yes/No)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  45. Safety and Tolerability: urinalysis - mucus

    Presence of mucus (Yes/No)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  46. Safety and Tolerability: urinalysis - bacteria

    Presence of bacteria (Yes/No)

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  47. Safety and Tolerability: urinalysis (microscopy)

    Microscopy of urine sediment is performed if it is present

    Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)

  48. Safety and Tolerability: blood chemistry - glucose

    Glucose concentration (mmol/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  49. Safety and Tolerability: blood chemistry - cholesterol

    Total cholesterol concentration (mmol/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  50. Safety and Tolerability: blood chemistry - protein

    Total protein concentration (g/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  51. Safety and Tolerability: blood chemistry - bilirubin

    Total bilirubin concentration (micromol/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  52. Safety and Tolerability: blood chemistry - creatinine

    Creatinine concentration (micromol/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  53. Safety and Tolerability: blood chemistry - alkaline phosphatase

    Alkaline phosphatase activity (U/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  54. Safety and Tolerability: blood chemistry - alanine transaminase

    Alanine transaminase activity (U/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  55. Safety and Tolerability: blood chemistry - aspartate transaminase

    Aspartate transaminase activity (U/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  56. Safety and Tolerability: blood chemistry - potassium concentration

    Potassium (mmol/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  57. Safety and Tolerability: blood chemistry - sodium concentration

    Sodium concentration (mmol/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

  58. Safety and Tolerability: blood chemistry - chloride concentration

    Chloride concentration (mmol/L)

    Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)

07

Study locations

1 of 1 sites recruiting
  • State Budgetary Healthcare Institution of the City of Moscow "City Clinical Hospital No. 15 named after O.M. Filatov of the Department of Health of Moscow."
    Moscow, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 11 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Mar 5, 2025
StartActual
Jan 13, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06859333
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Jan 13, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion